Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

5 de diciembre de 2011 actualizado por: Sirius Genomics Inc.

A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]

The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death. This will be an international, multicenter, "prospective-retrospective", nonrandomized, controlled, outcome-blinded, genotype-blinded, matched-patients study. No prospective enrollment or treatment of patients will occur under this protocol. Retrospectively collected clinical data and DNA samples will be analyzed for existing cohorts of patients with severe sepsis who were previously treated with DrotAA (treatment group) or not (control group) as part of their standard care in an ICU.

Descripción general del estudio

Estado

Desconocido

Condiciones

Descripción detallada

This will be a multicenter, "prospective-retrospective", controlled, matched-patients study. Retrospective phenotypic data and DNA samples will be obtained from patient registries and clinical trials where the study hypotheses were not related to DrotAA treatment. The prospective aspect of this study will be the statistical testing of prespecified hypotheses regarding the IRP genotype as a predictive biomarker for differential DrotAA treatment effects.

To control for differences in standard of care in different countries and medical centers, the selection of matched control patients will be performed within each cohort. Control patients will be selected to match the DrotAA-treated patients using an algorithm that matches on baseline demographic and disease characteristics that may have influenced the decision to give DrotAA or that may impact survival. A propensity score (the likelihood for having received DrotAA treatment) will be derived using the matching variables that are common in all cohorts. The number of matched control patients for each treated patient will be variable, up to a maximum of 3.

The selection of the control patients via the matching algorithm will be conducted by an independent clinical research organization (CRO) in a blinded manner - specifically without knowledge of survival outcome, other outcome data, and genotype. A two-phase transfer of data from each center will be implemented to ensure that the selection of matched control patients is implemented in a blinded manner. The first step will involve the transfer of the baseline data for all variables needed to conduct the matching. Once the control patients have been identified for each cohort, the outcomes data will be transferred to the CRO in the second phase of data transfer.

Centralized genotyping using a validated Taqman®-based analytical method will be conducted on the DNA samples for all matched patients. The genotyping laboratory will be blinded to treatment and outcome.

The total number of patients in the available cohorts is >23,000, with approximately 800 who have received DrotAA as part of their standard ICU-based care. After applying eligibility criteria to all patients and selecting the matched control patients, it is expected that the final analysis will include approximately 3000 patients.

Tipo de estudio

De observación

Inscripción (Anticipado)

3000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Canadá
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6Z 1Y6
        • University of British Columbia and Providence Health Care, St. Paul's Hospital
  • Estados Unidos
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University School of Medicine
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21224
        • Johns Hopkins University, Bayview Medical Center
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Harvard University School of Public Health
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 73232-2650
        • Vanderbilt University Schoo of Medicine
  • Francia
      • Garches, Francia, 92380
        • University of Versailles, Hospital Raymond Poincaré (AP-HP)
      • Paris, Francia, 75014
        • Université Paris Descartes, Sorbonne Paris Cité, Cochin Hotel-Dieu University Hospital
  • Reino Unido
      • London, Reino Unido, W6 8RF
        • Imperial College London, Charing Cross Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

The indicated-patients population (INDICATED) population will be the primary population for this study and it will include those DrotAA-treated patients who have documented severe sepsis and high risk of death, defined in keeping with the regulatory approvals in the EU and US, and their matched controls. Documented organ dysfunction will be defined according to published criteria. A secondary severe sepsis population (SEVSEP) will have had documented severe sepsis, but not necessarily a high risk of death. The INDICATED population will be a subset within the broader SEVSEP population.The SEVSEP population will be analyzed only if at least 10% larger than the INDICATED population.

Descripción

Inclusion Criteria for INDICATED population:

  1. Age ≥ 18 years

  2. Severe sepsis (must meet a, b, and c below)

    • Suspected or proven infection

    • Systemic Inflammatory Response Syndrome (SIRS)(must meet 2 of 4 criteria)

      • Temperature < 36°C or > 38°C
      • Heart rate > 90 beats/minute
      • Respiratory rate > 20 breaths/minute or PaC02 < 32 mm Hg) or on mechanical ventilation
      • White blood cell count < 4,000/mm3 or > 12,000/mm3

    • At least one organ dysfunction due to sepsis based on definitions of clinically significant organ dysfunction

      • Cardiovascular dysfunction [must meet one of (1), (2), or (3) below]:

        • Systolic blood pressure ≤ 90 mmHg and pH ≤ 7.3
        • Mean arterial pressure ≤ 70 mmHg and pH ≤ 7.3
        • Reported use of a vasopressor alone is sufficient evidence of shock
      • Pulmonary dysfunction: PaO2/FiO2 ≤ 300 mmHg
      • Central Nervous System dysfunction: Glasgow Coma Scale ≤ 12
      • Coagulation dysfunction: platelets ≤ 80,000/mm3
      • Renal dysfunction: creatinine ≥ 2.0 mg/dL
      • Hepatic dysfunction: bilirubin ≥ 2.0 mg/dL

  3. High risk of death (one of a, b, or c below)

    • APACHE II ≥ 25
    • SAPS II ≥ 54
    • Multiple organ dysfunction - two or more clinically significant organ dysfunctions (as defined above), which have occurred within 2 days of each other
  4. Platelet counts ≥ 30,000/mm3
  5. DrotAA status known

Exclusion Criteria:

  1. Patients with no DNA
  2. Patients enrolled in local cohort more than 2 years before Xigris [drotrecogin alfa activated)] was commercially available

A secondary analysis population with severe sepsis will be defined by Inclusion Criteria 1, 2, 4, and 5 above, and the Exclusion Criteria. This will be referred to as the SEVSEP population.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
DrotAA Treatment Group
Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
Control Group (non-DrotAA treated)
Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
In-hospital mortality through Day 28
Periodo de tiempo: Through Day 28.
All cause in-hospital mortality up to Day 28 or discharge, whichever comes first. Day 1 is the day when patient meets eligibility criteria for this study.
Through Day 28.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Time to death in hospital
Periodo de tiempo: Through Day 28
Time to death (any cause) in hospital, censored by the competing risk of discharge from hospital
Through Day 28
Time to death
Periodo de tiempo: Through Day 60
Time to death (any cause), censored at Day 60 or last evaluation. Will be evaluated using data from centers where follow-up extended beyond hospital discharge.
Through Day 60
Mechanical ventilator-free days through Day 28
Periodo de tiempo: Through Day 28
Number of days alive and free of mechanical ventilation from Day 1 through Day 28.
Through Day 28
ICU-free days through Day 28
Periodo de tiempo: Through Day 28
Number of days alive and free of ICU from Day 1 through Day 28.
Through Day 28
Hospital-free days through Day 28
Periodo de tiempo: Through Day 28
Number of days alive and free of hospitalization from Day 1 through Day 28.
Through Day 28
ICU length of stay
Periodo de tiempo: Through Day 180
Through Day 180
Hospital length of stay
Periodo de tiempo: Through Day 180
Through Day 180

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Sirius Genomics Inc.

Investigadores

  • Investigador principal: Djillali Annane, MD, PhD, University of Versailles
  • Director de estudio: Alexandra DJ Mancini, MSc, Sirius Genomics Inc.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de octubre de 2011

Finalización primaria (Anticipado)

1 de abril de 2012

Finalización del estudio (Anticipado)

1 de abril de 2012

Fechas de registro del estudio

Enviado por primera vez

2 de diciembre de 2011

Primero enviado que cumplió con los criterios de control de calidad

5 de diciembre de 2011

Publicado por primera vez (Estimar)

6 de diciembre de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

6 de diciembre de 2011

Última actualización enviada que cumplió con los criterios de control de calidad

5 de diciembre de 2011

Última verificación

1 de diciembre de 2011

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • SGX301

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Shock séptico

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Montenegro

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

3
Suscribir